What if Oprah Knew About Fractyl Health?
People like Oprah Winfrey have struggled to maintain their weight loss after weaning themselves off GLP-1s. What if an outpatient medtech procedure did the trick?
Eli Lilly Drug for 3 Obesity Targets Sets New High Bar for Weight Loss in a Clinical Trial
The high dose of Eli Lilly’s retatrutide led to an average 28.7% loss in body weight measured at 68 weeks. These Phase 3 results are the first from the experimental obesity drug’s broad clinical trial program, which is on track to yield seven data readouts in the coming year.
presented by
RCM Outsourcing: Balancing Human Expertise & Smart Technology
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
Novo Nordisk Swoops In With $6.5B Bid to Top Pfizer’s M&A Deal With Obesity Biotech Metsera
Acquisition talks for Metsera that played out this year culminated in an agreement with Pfizer, which agreed to buy the obesity drug developer for $4.9 billion. Novo Nordisk, a finalist in that pursuit, is positioning itself as a deal spoiler with a new unsolicited offer that shells out much more upfront cash.
Pfizer’s $4.9B Metsera Acquisition Positions It to Become Major Player in Obesity Drugs & More
Pfizer is acquiring Metsera and its pipeline of obesity medications that could offer dosing and tolerability advantages for patients as well as a manufacturing edge for the pharma giant. Key data Phase 2 readouts for Metsera’s lead GLP-1 drug candidate are expected in 2026.
Side Effects Make Viking’s Oral Obesity Drug a Tough Pill for Investors to Swallow
Viking Therapeutics’ obesity pill met weight reduction goals of its Phase 2 test, but gastrointestinal side effects led to high discontinuation rates. Even so, analysts see potential for a lower dose of the Viking drug as a maintenance therapy.
presented by
The Best Group Nutrition Programs for Weight Loss: A Comprehensive Guide
Everyone has a different idea or method for losing weight. These leaders in nutrition offer guidance on finding the right fit.
presented by
MedCity News Pivot Podcast: How Emergency Departments Are Using Real-Time Data to Improve Outcomes
How can AI benefit and improve patient outcome in the emergency department? Watch the latest episode to find out.
Knownwell Opens 6 New Clinics in Chicago
Obesity care company knownwell expanded into six new clinic locations across greater Chicago. The company now operates eight clinics, as it has existing locations in Boston and Dallas. Knownwell also provides virtual care services to patients across New England, Texas and Illinois.
Metabolic Meds Startup Verdiva Launches With $411M and a Weekly Oral GLP-1 Drug
Verdiva Bio’s once-a-week oral GLP-1 drug is ready for Phase 2 testing. The drug, made with a proprietary technology that enables oral dosing, was licensed from Sciwind Biosciences.
Biopharma in 2025: Outlook for Obesity Meds, Drug Prices, Regulation & More
Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things to look for include more widespread adoption of artificial intelligence technologies and the IPO market’s return to normal levels.
A New Era in OSA: Bridging the Gap with Novel Treatment Solutions
We must think beyond one-size-fits-all solutions and embrace the diversity of obstructive sleep apnea. This means continuing to innovate, collaborating across sectors, and keeping patients at the center of every decision.
presented by
Esperion Sets Its Sights on New Areas While Maintaining Commitment to Cardiovascular Health
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases
The Chase for Novel Oral GLP-1 Obesity Meds Adds a New Contender
Corxel Pharmaceuticals has acquired an oral small molecule GLP-1 agonist with potential applications in obesity and diabetes. The Phase 2-ready pill could compete with oral metabolic meds in development by companies such as Roche, AstraZeneca, and Structure Therapeutics.
Video: Battle of the Bulge – Wegovy vs. Zepbound
The GLP-1 battle heats up with new preliminary data from Eli Lilly showing that patients using its weight loss drug Zepbound lost more weight on average in 72 weeks than those on Novo Nordisk's Wegovy.
Weight Loss With Amgen Drug in Line With Eli Lilly Med, But Dosing Could Be Differentiator
Amgen’s experimental obesity drug, MariTide, led to an average 20% reduction in weight in a Phase 2 clinical trial. While investors hoped for greater weight loss, some analysts say less burdensome monthly dosing of MariTide could make it competitive against weekly injectable weight drugs Zepbound and Wegovy.
A Recipe for Better Obesity Care: Integrating GLP-1s with Food as Medicine
Nutrition isn’t a supplement — it’s foundational to metabolic health. It’s time we integrate more ‘Food as Medicine’ initiatives alongside the GLP-1 therapies that are gaining traction.
Exercise Benefit in a Pill: BioAge Labs Goes Public, Raising More Than $200M for Clinical Trials
BioAge Labs’ lead drug candidate, azelaprag, is in Phase 2 testing in combination with Eli Lilly’s weight management medication Zepbound. The biotech’s oral drug activates a receptor it says can mimic certain biological effects of exercise.